AstraZeneca (AZN.L,AZN) and Daiichi Sankyo's (DSKYF.PK) datopotamab deruxtecan (Dato-DXd) did not significantly improve overall survival for adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer, according to detailed results from the TROPION-Lung01 Phase III trial.Jacob Sands, MD, Dana-Farber Cancer Institute, Medical Oncology and investigator in the trial, said: 'Despite many efforts to surpass docetaxel with novel approaches in previously treated advanced or metastatic non-small cell lung cancer, patients only survive for about one year.The TROPION-Lung01 Phase III trial evaluated AstraZeneca and Daiichi Sankyo's datopotamab deruxtecan compared to docetaxel, the current standard of care chemotherapy, in adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) who had received at least one prior line of therapy.Datopotamab deruxtecan is a specifically engineered TROP2-directed DXd antibody drug conjugate discovered by Daiichi Sankyo and being jointly developed by AstraZeneca and Daiichi Sankyo.In the overall trial population, overall survival results numerically favoured datopotamab deruxtecan compared to docetaxel (12.9 versus 11.8 months) but did not reach statistical significance, according to the companies.In the prespecified subgroup of patients with nonsquamous NSCLC, datopotamab deruxtecan showed a 2.3-month improvement in overall survival compared to docetaxel (14.6 versus 12.3 months; HR 0.84; 95% CI 0.68-1.05)..

根据TROPION-Lung01 III期临床试验的详细结果，阿斯利康（AZN.L，AZN）和第一三共（DSKYF.PK）达托帕单抗（datopotamab deruxtecan，Dato DXd）并未显着改善局部晚期或转移性非鳞状非小细胞肺癌成年患者的总生存期。Dana Farber癌症研究所医学肿瘤学博士兼该试验的研究者Jacob Sands说：“尽管在先前治疗的晚期或转移性非小细胞肺癌中，许多人努力用新方法超越多西紫杉醇，但患者只能存活约一年。TROPION-Lung01 III期临床试验评估了阿斯利康和第一三共公司的达托帕单抗deruxtecan与多西他赛（目前的标准化疗方案）相比，在接受过至少一种先前治疗的局部晚期或转移性非鳞状非小细胞肺癌（NSCLC）的成年患者中。Datopotamab deruxtecan是由Daiichi Sankyo发现并由AstraZeneca和Daiichi Sankyo联合开发的特异性工程TROP2定向DXd抗体-药物偶联物。据这些公司称，在总体试验人群中，与多西紫杉醇相比，总体生存结果在数值上有利于达托单抗-德鲁替康（12.9个月对11.8个月），但没有达到统计学意义。在预先指定的非鳞状细胞癌患者亚组中，与多西紫杉醇相比，达托单抗-德鲁替康的总生存期提高了2.3个月（14.6个月比12.3个月；HR 0.84；95%CI 0.68-1.05）。。

Meanwhile, AstraZeneca and Daiichi Sankyo noted that results from the NeoCOAST-2 Phase II platform trial evaluating Imfinzi (durvalumab) in multiple novel combinations, before and after surgery, in patients with early-stage (Stage IIA-IIIB) resectable NSCLC were featured in a WCLC Presidential Symposium.

与此同时，阿斯利康和第一三共指出，NeoCOAST-2 II期平台试验的结果评估了早期（IIA-IIIB期）可切除NSCLC患者手术前后多种新型组合的Imfinzi（durvalumab）在WCLC总统研讨会上的特点。

Preliminary results from the trial arm testing neoadjuvant Imfinzi plus datopotamab deruxtecan and carboplatin demonstrated a pathological complete response rate of 34.1% and a major pathological response rate of 65.9%. This was numerically higher than the response rates shown by other combination regimens tested, however, the trial was not powered to make direct statistical comparisons between arms, the companies said.The safety profile of Imfinzi plus datopotamab deruxtecan and carboplatin was consistent with the known safety profiles of these agents.

试验组测试新辅助Imfinzi加达托巴单抗deruxtecan和卡铂的初步结果显示，病理完全缓解率为34.1%，主要病理缓解率为65.9%。这些公司表示，这在数字上高于测试的其他联合治疗方案所显示的应答率，但是，该试验无法对两组进行直接的统计比较。Imfinzi加达托单抗deruxtecan和卡铂的安全性与这些药物的已知安全性一致。

Surgical rates across arms were comparable and in line with those shown in recent Phase III trials. AstraZeneca and Daiichi Sankyo are evaluating datopotamab deruxtecan in combination with Imfinzi in multiple ongoing trials.For More Such Health News, visit rttnews.com. For comments and feedback contact: editorial@rttnews.comBusiness News.

双臂手术率相当，与最近的III期临床试验结果一致。阿斯利康（AstraZeneca）和第一三共（Daiichi Sankyo）正在多个正在进行的试验中评估达托巴单抗（datopotamab deruxtecan）联合Imfinzi。有关更多此类健康新闻，请访问rttnews.com。如需评论和反馈，请联系：editorial@rttnews.comBusiness新闻。

Biotech Stocks Facing FDA Decision In August 2024

2024年8月美国食品和药物管理局（FDA）决定生物技术股

Biotech Stocks Facing FDA Decision In June 2024

2024年6月美国食品和药物管理局决定生物技术股

Biotech Stocks Facing FDA Decision In April 2024

2024年4月美国食品和药物管理局（FDA）决定生物技术股